EDINBURGH, Scotland--(BUSINESS WIRE)--IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, today announces the appointment of Rakesh Patel as a Non-Executive Director. Mr Patel will join the Board of Directors with immediate effect.
Mr Patel is currently a Managing Director and Co-Head of European Healthcare Banking at J.P. Morgan in London. He joined J.P. Morgan in 2008 from Novartis where he was Global Head of M&A for Novartis Pharma AG. Prior to joining Novartis, Mr Patel was Vice President in the European Healthcare team at Morgan Stanley.
Cancer immunotherapy is an exciting and rapidly growing field of research investigating the use of therapies that harness the body’s own immune system in the fight against cancer. IOmet is developing multiple, distinct novel chemical series of potent, IDO1-selective, TDO-selective and dual-acting IDO1/TDO inhibitors. IDO1 (indoleamine-2,3-dioxygenase 1) and TDO (tryptophan-2,3-dioxygenase), the rate-limiting enzymes in the pathway that metabolises the essential amino acid tryptophan, have emerged as key targets for the pharmaceutical industry in the cancer immunotherapy field.
Compared to IDO1 and TDO inhibitors identified to date, IOmet’s compounds demonstrate highly favourable in vitro human and rodent PK properties, which translate to superior in vivo PK/PD relationships. Uniquely, IOmet’s inhibitors encompass IDO1-specific, TDO-specific and IDO1/TDO dual inhibitors.
About Iomet Pharma
IOmet Pharma Ltd is a privately-held drug discovery company based in Edinburgh, UK. Founded in 2008, IOmet is focused on the development of innovative medicines for the treatment of cancer, with particular emphasis on the fields of cancer immunotherapy and cancer metabolism. IOmet has a team with a proven track record of success in bringing small molecules from discovery phase to the clinic, and is advised by internationally-renowned experts in the fields of cancer immunotherapy (Prof Holbrook Kohrt, Stanford Cancer Institute) and oncology drug development (Dr Rob Williams, Chief Drug Development Scientist, Cancer Research UK (CRUK) and Dr Ian Waddell, Head of Biology, Drug Discovery Unit, CRUK Manchester Institute). For more information, please visit www.iometpharma.com